Inovio Pharmaceuticals (GBM) Price & Analysis

6 Followers

GBM Stock Chart & Stats

€0.89

-€0.05(-5.46%)

At close: Jul 27 4:00 PM EDT

€0.89

-€0.05(-5.46%)

Day’s Range― - ―

52-Week Range€0.83 - €2.48

Previous CloseN/A

Volume10.38K

Average Volume (3M)950.00

Market Cap

€69.71M

Enterprise Value€91.25

Total Cash (Recent Filing)€37.68M

Total Debt (Recent Filing)€8.70M

Price to Earnings (P/E)―

Beta0.97

Next Earnings

Aug 12, 2026

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.71

Shares Outstanding82,273,240

10 Day Avg. Volume2,837

30 Day Avg. Volume950

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)3.39

Price to Sales (P/S)1248.52

P/FCF Ratio-0.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€3.74

Price Target Upside319.87% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.8

Revenue Forecast (FY)€586.17K

Bulls Say, Bears Say

Bulls Say

Regulatory ProgressAcceptance of the BLA and a defined PDUFA date create a clear regulatory timetable and materially reduce binary uncertainty long term. A mid‑cycle review with no new issues suggests the submission is substantively complete, enabling commercialization planning and partner negotiations if approval succeeds.

Compelling Clinical EfficacyDurable Phase I/II results showing large reductions in surgeries and improved safety support a meaningful clinical benefit and differentiated product profile. Such sustained efficacy and tolerability underpin label strength, payer discussions, and potential faster adoption versus competitors over the medium term.

Platform & PartnershipsExternal collaborations and platform expansion diversify development risk and validate technology. Partnerships and new preclinical indications create multiple development and monetization pathways, increasing durable optionality beyond a single asset and enabling non‑dilutive or co‑funded development strategies.

Bears Say

Tight Cash RunwayPost‑offering cash extending only to Q1 2027 (excluding more raises) leaves limited headroom given estimated ~$18M quarterly burn. This structural funding gap increases the probability of near‑term capital raises, potential dilution, constrained commercial investment, or forced dependence on partners for pivotal activities.

Persistent Negative Cash FlowChronic negative operating and free cash flow, with TTM pressure, indicate the company cannot self‑fund operations or expansion. Sustained losses limit reinvestment capacity, heighten refinancing needs, and weaken negotiating leverage with partners and payers over the medium term.

Regulatory & Competitive Execution RiskAn FDA question about accelerated‑approval eligibility leaves confirmatory trial design and approval timing unresolved, increasing execution risk. Coupled with an existing commercial competitor (PAPZIMEOS), these structural regulatory and first‑mover challenges raise uncertainty about market entry speed and achievable uptake.

Inovio Pharmaceuticals News

Inovio files $300M mixed securities shelf

16:03 EDT Inovio (INO) files $300M mixed securities shelf Published first on TheFly – the ultimate source for...

27d ago

INO

Inovio price target lowered to $2.50 from $3 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Inovio (INO) to $2.50 from $3 and keeps a Neutral...

2M ago

INO

Inovio: ApolloBio announces ‘positive’ results from Phase 3 trial of VGX-3100

Inovio (INO) announced that its partner for VGX-3100 in China, ApolloBio, announced positive topline results from its pivotal...

2M ago

INO

Inovio Shareholders Endorse Governance Changes and Leadership

The latest announcement is out from Inovio Pharmaceuticals ( ($INO) ). On May 19, 2026, Inovio Pharmaceuticals amended...

2M ago

INO

Inovio’s INO‑3107 Nears PDUFA Amid Cash Squeeze

Inovio Pharmaceuticals (($INO)) has held its Q1 earnings call. Read on for the main highlights of the call....

2M ago

INO

Inovio Pharmaceuticals Earnings Call: Progress Amid Cash Strain

Inovio Pharmaceuticals (($INO)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

INO

Inovio reports Q1 EPS (28c), consensus (33c)

Estimates current cash, cash equivalents and short-term investments balances sufficient into 1Q27, beyond the target PDUFA date for...

3M ago

INO

Inovio options imply 15.1% move in share price post-earnings

Pre-earnings options volume in Inovio (INO) is normal with calls leading puts 72:1. Implied volatility suggests the market...

3M ago

INO

Options Volatility and Implied Earnings Moves Today, May 13, 2026

Today, several major companies are expected to report earnings: Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Microvision (MVIS), Toyota...

3M ago

INO

Options Volatility and Implied Earnings Moves This Week, May 11 – May 14, 2026

This week, several major companies will be reporting earnings. Among them are Alibaba (BABA), Plug Power (PLUG), D-Wave...

3M ago

Is INO a Buy, Before Earnings?

Inovio Pharmaceuticals (INO) is scheduled to report 1st quarter earnings on 05/13/2026, after the market closes. Regarding Q1...

3M ago

INO

Inovio Pharmaceuticals Announces New Public Equity Offering

Inovio Pharmaceuticals ( ($INO) ) has issued an announcement. On April 2, 2026, Inovio Pharmaceuticals, Inc. entered into...

4M ago

INO

Inovio Pharmaceuticals Suspends Existing At-the-Market Stock Program

Inovio Pharmaceuticals ( ($INO) ) just unveiled an announcement. On April 1, 2026, Inovio Pharmaceuticals, Inc. notified Oppenheimer...

4M ago

INO

Inovio files to sell common stock, no amount given

Piper Sandler is acting as sole manager for the offering. Published first on TheFly – the ultimate source...

4M ago

INO

GBM FAQ

What was Inovio Pharmaceuticals’s price range in the past 12 months?

Inovio Pharmaceuticals lowest stock price was €0.83 and its highest was €2.48 in the past 12 months.

What is Inovio Pharmaceuticals’s market cap?

Inovio Pharmaceuticals’s market cap is €69.71M.

When is Inovio Pharmaceuticals’s upcoming earnings report date?

Inovio Pharmaceuticals’s upcoming earnings report date is Aug 12, 2026 which is in 14 days.

How were Inovio Pharmaceuticals’s earnings last quarter?

Inovio Pharmaceuticals released its earnings results on May 13, 2026. The company reported -€0.246 earnings per share for the quarter, beating the consensus estimate of -€0.307 by €0.061.

Is Inovio Pharmaceuticals overvalued?

According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Inovio Pharmaceuticals pay dividends?

Inovio Pharmaceuticals does not currently pay dividends.

What is Inovio Pharmaceuticals’s EPS estimate?

Inovio Pharmaceuticals’s EPS estimate is -0.19.

How many shares outstanding does Inovio Pharmaceuticals have?

Inovio Pharmaceuticals has 82,273,240 shares outstanding.

What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?

Inovio Pharmaceuticals reported an EPS of -€0.246 in its last earnings report, beating expectations of -€0.307. Following the earnings report the stock price went down -3.085%.

Which hedge fund is a major shareholder of Inovio Pharmaceuticals?

Currently, no hedge funds are holding shares in DE:GBM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Inovio Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-42.96%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.

Inovio Pharmaceuticals (GBM) Earnings & Revenues

Historic Earnings Reports

GBM Company Deck

GBM Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed substantial progress on multiple fronts—regulatory milestones (BLA accepted, mid-cycle review with no new issues, PDUFA date set), strong Phase I/II efficacy/safety signals, commercial preparation and advancing partnerships—tempered by material near-term financial constraints (cash declined ~36%, an $18M estimated Q2 burn and runway into only Q1 2027), outstanding regulatory questions about accelerated approval eligibility and an active competitive landscape. Overall the tone was optimistic about the program and platform advancement but realistic about financing and regulatory uncertainties.View all DE:GBM earnings summaries

GBM Stock 12 Month Forecast

Average Price Target

€3.74

▲(319.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","-1":"-€1","0.75":"€0.75","2.5":"€2.5","4.25":"€4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5.275504440000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€5.28</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.736815645,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€3.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.19812685,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.20</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.945,1.278115726153846,1.6112314523076923,1.9443471784615385,2.2774629046153847,2.610578630769231,2.9436943569230767,3.276810083076923,3.609925809230769,3.9430415353846153,4.2761572615384615,4.609272987692308,4.942388713846154,{"y":5.275504440000001,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.945,1.1597550496153846,1.3745100992307693,1.5892651488461538,1.8040201984615385,2.018775248076923,2.2335302976923077,2.448285347307692,2.663040396923077,2.8777954465384616,3.092550496153846,3.3073055457692306,3.5220605953846156,{"y":3.736815645,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.945,1.041394373076923,1.137788746153846,1.234183119230769,1.3305774923076923,1.4269718653846155,1.5233662384615383,1.6197606115384615,1.7161549846153847,1.8125493576923077,1.9089437307692307,2.005338103846154,2.1017324769230767,{"y":2.19812685,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.944,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.099,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.945,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >